Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables: 2022-2024

Historic Payables for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $3.3 million.

  • Day One Biopharmaceuticals' Payables rose 91.51% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year decrease of 0.87%. This contributed to the annual value of $3.3 million for FY2024, which is 26.63% up from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Payables is $3.3 million, which was up 26.63% from $2.6 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Payables peaked at $15.9 million during FY2022, and registered a low of $2.6 million during FY2023.
  • For the 3-year period, Day One Biopharmaceuticals' Payables averaged around $7.3 million, with its median value being $3.3 million (2024).
  • Its Payables has fluctuated over the past 5 years, first crashed by 83.85% in 2023, then grew by 26.63% in 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' Payables (Yearly) stood at $15.9 million in 2022, then tumbled by 83.85% to $2.6 million in 2023, then rose by 26.63% to $3.3 million in 2024.